Manchester Management Co. LLC is 10% Owner at FENNEC PHARMACEUTICALS INC. (FENC). They have made 12 open-market trades across 4 companies since 2014, most recently 2025-12-10.
10 open-market purchases totalling $7.2M since 2014, against 2 sales. Across 9 scored buys the stock is down 17.4% at ninety days, and 19.0 points behind the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| FENC | 2,004,057 | $20.1M |
| MODD | 3,284,743 | $7.5M |
| SNWV | 872,605 | $4.4M |
| CLOK | 3,645,500 | — |
| Total | $31.9M |
Shares reported on the most recent Form 4, priced at the 2025-12-10 close. 1 holding could not be priced and is excluded from the total.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 78% | 67% | 0% |
| Avg Move | +5.7% | -2.7% | -17.4% |
| Alpha | +6.3% | -3.6% | -19.0% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SNWV | SELL | 2025-12-09 | 2025-12-10 | $30.49 | $531K | +2.7% | +2.6% | -25.7% |
| MODD | BUY | 2024-11-21 | 2024-11-25 | $1.50 | $250K | -1.7% | -17.4% | -39.8% |
| SNWV | BUY | 2024-10-18 | 2024-10-23 | $8.25 | $3.0M | +0.7% | -8.1% | -8.1% |
| MODD | BUY | 2018-11-20 | 2021-10-29 | $2.25 | $2.9M | -31.3% | -10.6% | -10.6% |
| CLOK | BUY | 2018-10-31 | 2018-11-01 | $1.85 | $48K | N/A | N/A | N/A |
| FENC | SELL | 2017-04-12 | 2018-03-29 | $9.23 | $706K | +13.9% | +2.0% | -16.4% |
| FENC | BUY | 2017-02-28 | 2018-03-29 | $8.34 | $500K | +13.9% | +2.0% | -16.4% |
| FENC | BUY | 2016-08-23 | 2018-03-29 | $2.01 | $96K | +13.9% | +2.0% | -16.4% |
| FENC | BUY | 2015-12-29 | 2018-03-29 | $1.78 | $36K | +13.9% | +2.0% | -16.4% |
| FENC | BUY | 2015-05-27 | 2018-03-29 | $1.65 | $85K | +13.9% | +2.0% | -16.4% |
| FENC | BUY | 2014-12-24 | 2018-03-29 | $2.47 | $179K | +13.9% | +2.0% | -16.4% |
| FENC | BUY | 2014-08-29 | 2018-03-29 | $2.48 | $103K | +13.9% | +2.0% | -16.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.